Equibles does not estimate personal net worth.
Get an email with a short summary when Ligand Pharmaceuticals Inc publishes a filing, an earnings call transcript or a press release.
Get LGND alertsTodd Davis is recorded as CEO at Ligand Pharmaceuticals Inc (LGND). Todd Davis has spoken on 16 earnings calls across 1 company, most recently for Ligand Pharmaceuticals Inc on October 29, 2026. Ligand Pharmaceuticals Inc is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Ligand Pharmaceuticals Inc includes Todd C. Davis (CEO and Board Member), Tavo Espinoza (CFO), Jason Haas (Board Member) and 7 others.
“The third quarter was an important one for Ligand, with royalty revenue growing 51% year-over-year to approximately $70 million. Filspari, O2Vair, and the addition of the Zoma commercial assets, Vibaismo, Ojemda, and MyPlaifa led that growth, with the Filspari launch and FSGS being a primary growth driver as well.”
“We continue to execute on the financial transformation of Ligand. In the second quarter, we continue to deliver outstanding financial performance while executing on two initiatives that significantly strengthen and position our long-term growth platform.”
“2026 is off to an exciting start for Ligand with transformative milestones within our existing portfolio and through the anticipated acquisition of Zoma Royalty Corporation that we announced last week.”
“We delivered exceptional financial performance with full-year adjusted EPS exceeding our original 2025 guidance by more than 30%.”
“Not only did we deliver another quarter of exceptional financial results, we also successfully completed a convertible debt financing, providing us with additional flexibility to pursue strategic opportunities that support our growth initiatives.”
Biotechnology · Healthcare
CEO
